A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Deep IL-12 primed T cells (Primary)
- Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Torque Therapeutics
- 23 Jan 2019 Status changed from planning to recruiting.
- 29 Nov 2018 New trial record
- 12 Nov 2018 According to a Torque Therapeutics media release, the company plans to initiate this trial in 2019.